Methods for measuring, diagnosing, treating and managing metabolic syndrome

Abstract

The present invention relates to a method for measuring, diagnosing, treating and managing metabolic syndrome, including administering metabolic syndrome treatment drugs and pharmaceuticals to a patient in need of monitoring using an electronic device to prevent or reduce the risk of metabolic syndrome and related diseases, characterized in that it comprises the following steps: collecting and storing patient identification information and / or body measurement information in a database for incorporation into a medical record; referring the patient to a medical professional for medical record consultation; providing a pharmaceutical composition, supplying or supporting device comprising a pharmaceutical useful for preventing, reducing or controlling metabolic syndrome; connecting one or more measuring devices for measuring body metric information using an interactive user interface; measuring, recording and storing the collected body metric information in a database; the medical professional monitoring the patient's body metric information; and adjusting or maintaining a course of treatment.

Description

[Technical field]

[0001] The present invention relates to a useful method for the measurement, diagnosis, treatment and management of metabolic syndrome, including administration of formulations to prevent or reduce the risk of metabolic syndrome and related diseases, by remote medical care and distribution of formulations and supplies through the use of a user interface that allows for intercommunication between a physician and / or patient with a measurement device associated with a set of essential elements to meet treatment goals. [Background technology]

[0002] Metabolic syndrome is a constellation of risk factors that develop when at least three of the following are present: waist circumference 40 inches or more in men and 35 inches or more in women, triglycerides 150 milligrams per deciliter (mg / dL) or more of blood, high-density lipoprotein (HDL) cholesterol less than 40 mg / dL in men and less than 50 mg / dL in women, fasting blood glucose 100 mg / dL or more, systolic blood pressure 130 mmHg or more and / or diastolic blood pressure 85 mmHg or more, resulting in an increased risk of cardiovascular disease, diabetes, blood clots, fatty liver disease, and other health problems.

[0003] Metabolic syndrome can develop from lack of physical activity, overweight, obesity or genetic conditions and, if poorly treated or managed, can render an individual physically incapacitated and adversely affect their ability to carry out daily activities.

[0004] Specifically, overweight and obesity are defined as abnormal or excessive accumulation of fat that may be harmful to health. Currently, there are over 1.9 billion people aged 18 and over who are overweight, of which 650 million have some form of obesity, while over 380 million people under the age of 18 are overweight or obese, which the World Health Organization classifies as a global pandemic.

[0005] According to the US Centers for Disease Control and Prevention (CDC), body mass index (BMI) is weight (in kilograms) divided by height (in meters) squared, and a high BMI may be an indicator of excess body fat.

[0006] In this regard, the CDC suggests the following BMI ranges to identify the presence of overweight and obesity: -A BMI below 18.5 falls into the underweight range. - A BMI between 18.5 and 25 falls into the healthy weight range. - A BMI between 25.0 and 30 falls into the overweight range. - A BMI of 30.0 or higher falls into the obese range. Obesity is further subdivided into three classes according to BMI. - Class 1: BMI 30 or more and less than 35. - Class 2: BMI 35 or more and less than 40. - Class 3: BMI 40 or more, "severe" obesity.

[0007] Compared to people of a healthy weight, overweight people are at higher risk of many serious diseases and health conditions, including high blood pressure, high LDL cholesterol, low HDL cholesterol or high triglycerides (dyslipidemia), type 2 diabetes, coronary heart disease, stroke, gallbladder disease, osteoarthritis (destruction of cartilage and bone in the joints), sleep apnea and breathing disorders, some types of cancer, reduced quality of life, psychiatric disorders such as clinical depression, anxiety and other mental disorders, physical pain and impaired physical function.

[0008] As described above, obesity and overweight are major risk factors for the development of metabolic syndrome, but they are also easily detectable factors and can be prevented or managed at any stage.

[0009] Access to healthcare professionals who specialize in metabolic syndrome and related disorders is complicated by the fact that it is usually based on referral, or by choosing to self-treat without any contact with such professionals, or by using medications or exercise equipment to lose weight or improve one's health, and patients may discontinue or drop out of treatment due to lack of time / willingness to see a physician and physicians' time to adequately serve the patient, and lack of time / willingness to treat patients and a shortage of healthcare providers to provide it.

[0010] While there are many approaches to weight management or loss, patients commonly turn to dieting, exercise and therapy without a proper treatment plan or the assistance of a medical professional, which can result in patient distress, excessive weight gain after the diet ends, ill health and even death.

[0011] When treating overweight and obesity with dietary supplements or medicines, monitoring throughout treatment, and the participating health professionals, is essential to avoid compromising the patient's health. Summary of the Invention [Problem to be solved by the invention]

[0012] Since patients' health is compromised when it is difficult to continue preventive treatment or management of overweight, obesity and other factors of metabolic syndrome, a monitoring system is needed that is continuously accessible to healthcare professionals and has a drug or drug stocking system during the administration of medicines, with the aim of ensuring the supply of medicines, supplements, consumables, or support devices for quality and safe measurement, providing continuity and motivation to continue treatment, and, with the help of technology, monitoring in real time indicators that allow healthcare professionals to know the progress of treatment and evaluate whether the treatment plan needs to be changed or maintained.

[0013] It is an object of the present invention to provide a useful method for the measurement, diagnosis, treatment and management of metabolic syndrome, including administering medicines to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using or by means of an electronic device, thereby enabling the allocation of appropriate treatment, as well as the supply of medicines, consumables and supporting devices required for real-time monitoring by medical personnel.

[0014] As a specific objective, the present invention provides various tools that facilitate adherence to treatment and subsequently provide ongoing recommendations regarding routines, diet, frequency of medical appointments, exercise, etc., among other activities that allow for treatment reinforcement and monitoring by the medical practitioner.

[0015] Another specific object of the present invention is to maintain a constant relationship between the patient and the medical professional, ensuring uninterrupted communication of data on both sides; to maintain a constant connection between the patient and the drug provider, supplies or necessary support devices, avoiding discontinuation of treatment due to shortages thereof and to inform and remind the patient before any of them are terminated; and to maintain a connection between the patient and the measurement device, avoiding the need for data transfer or errors that may occur during the transfer.

[0016] The present invention relates to a method of management useful in the diagnosis, measurement and treatment of metabolic syndrome, which involves administering a pharmaceutical agent to prevent or reduce the risk of metabolic syndrome. [Means for solving the problem]

[0017] A method for treating metabolic syndrome and related diseases using an electronic device, comprising: (a) Collect and store in a database patient identifying and body metric information for incorporation into the medical record. (b) Refer the patient to a health care provider who has expertise in metabolic syndrome and related disorders to evaluate the patient's health status. (c) Informing patients of their health status and recording it in their medical records. (d) instructing patients on a course of treatment for metabolic syndrome and / or related disorders or prevention of metabolic syndrome and / or related disorders; (e) Providing to a patient in need thereof a pharmaceutical composition comprising a pharmaceutical agent useful for preventing, ameliorating, or managing metabolic syndrome and / or related disorders. (f) Providing consumables or supportive devices for the prevention, mitigation, or management of metabolic syndrome and / or related diseases to patients in need. (g) Using an interactive user interface, connecting one or more measurement devices for measuring body metric information. (h) Measure, record and store in a database any collected body metric information. (i) Medical professionals specializing in metabolic syndrome and related diseases will monitor patients' body metric information data and evaluate the patient's health status. (j) adjusting or maintaining a course of treatment for metabolic syndrome and / or related disorders from which a patient suffers, or preventing metabolic syndrome and / or related disorders; (k) Optionally, for a set period of time or at the request of the patient or healthcare professional, healthcare professionals may provide assistance to the patient. [Brief description of the drawings]

[0018] [Figure 1] FIG. 1 is a flow diagram illustrating an embodiment of the present invention. [Diagram 2] FIG. 4 is a flow diagram illustrating another embodiment of the present invention. [Diagram 3] FIG. 4 is a flow diagram illustrating alternative embodiments of the present invention. [Figure 4] FIG. 1 is a flow diagram illustrating an embodiment of a system for monitoring body metric information of the present invention. [Diagram 5] FIG. 4 is a flow diagram illustrating another embodiment of the present invention. [Figure 6] FIG. 2 is a flow diagram illustrating an embodiment of using a measuring device and associated electronic device for measuring body metric indicators of the present invention. [Figure 7] FIG. 2 is a flow diagram illustrating an embodiment of a medical worker's use of an electronic device according to the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] The following are descriptions of exemplary embodiments consistent with the description of the present invention, where the "exemplary embodiments" include certain aspects, structures, or features that may be combined with other exemplary embodiments, whether described or not, and thus the exemplary embodiments described below are not limiting and different software or hardware embodiments, interfaces, execution means, storage or reading, instructions, etc. may be implemented.

[0020] FIG. 1 is a diagram illustrating a useful method for the measurement, diagnosis, treatment and management of metabolic syndrome, including administering medications to a patient in need (100) to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device, comprising the following features: Collecting (101) patient identification information (102a) and / or clinical parameters and / or body metric information (102c), which is information obtained when measuring body measurement indicators, etc., storing them in a database (103) and incorporating them into the medical record (102b), referring (111) the patient (100) to a medical professional (110) specializing in metabolic syndrome and related diseases for the evaluation of the patient's health status, presenting the patient's health status (111b) and recording it in the medical record (102b), and instructing the patient (111c) on a course of treatment for the metabolic syndrome and / or related diseases that the patient is suffering from, or a course of treatment for the prevention of metabolic syndrome and / or related diseases. and providing (121a) useful medicines (130) for the prevention, mitigation, or management of metabolic syndrome and / or related diseases to patients (100) in need thereof through a pharmacy (120). and providing (121b) to a patient (100) in need thereof a consumable (140a) or a support device (140b) for the prevention, mitigation, or management of metabolic syndrome and / or related diseases. Connecting (151) one or more measurement devices (140) for measuring body metric information using an interactive user interface (150). Measuring (141), recording (142) and storing (143) the collected body metric information (102c) in a database (103). A medical professional (110) specializing in metabolic syndrome and related diseases monitors (112) the patient's (100) body metric information (102c) data and evaluates the patient's health condition. To adjust or maintain a course of treatment for the metabolic syndrome and / or related disorders from which the patient is suffering, or to prevent the metabolic syndrome and / or related disorders (113). Optionally, a medical professional (110) provides assistance (114) to the patient (100) at set time periods or upon request of the patient or medical professional.

[0021] FIG. 2 illustrates one embodiment of a useful method for the measurement, diagnosis, treatment and management of metabolic syndrome, including administering medications to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device, comprising the following features: A pharmaceutical composition comprising a medicinal product (130) useful for preventing, reducing or managing metabolic syndrome and / or associated diseases is provided (121a) to a patient (100) from the patient's patient identification information (102a) and body metric information (102c) and / or medical records (102b) pre-stored in a database (103). A medical professional (110) specializing in metabolic syndrome and related diseases monitors (112) a patient's body metric information data via an interactive user interface (150) connected to one or more measurement devices for measuring the body metric information, and the interactive user interface (150) records (142) and stores (143) the body metric information.

[0022] FIG. 3 illustrates various embodiments of useful methods for measuring, diagnosing, treating, and managing metabolic syndrome, including administering medications to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device.

[0023] In one embodiment, a useful method for the measurement, diagnosis, treatment, and management of metabolic syndrome, comprising administering a pharmaceutical agent to a patient undergoing treatment prevention, mitigation, or management of metabolic syndrome and / or related diseases using an electronic device, the method comprising: Patient identification information (102a) and / or body metric information (102c) are collected (101) and stored in a database (103) to incorporate a medical record (102b). Through the pharmacy (120), a pharmaceutical composition containing a useful drug (130) for preventing, alleviating or managing metabolic syndrome and / or related diseases is provided (121a) to a patient (100) in need thereof based on patient identification information (102a) and the patient's body metric information (102c) and / or information in the patient's medical record (102b) previously stored in a database. Body metric information (102c) collected from the patient during treatment is measured (141), recorded (142) and stored (143) in a database (103). A medical professional (110) specializing in metabolic syndrome and related diseases monitors (112) the patient's (100) body metric information (102c) data to assess the patient's health status, adjust or maintain a treatment plan (113) for treating the metabolic syndrome and / or related diseases suffered by the patient, or prevent the metabolic syndrome and / or related diseases.

[0024] In one embodiment, a method useful for measuring, diagnosing, treating, and managing metabolic syndrome comprises administering a pharmaceutical agent to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device, characterized in that the method comprises the steps of: The patient (100) is referred (111) to a medical professional (110) who specializes in metabolic syndrome and related disorders for an evaluation of the patient's health status, the patient's health status (111b) is presented, and recorded in the medical record (102b), and the patient is instructed (111c) on a course of treatment for the metabolic syndrome and / or related disorders from which the patient suffers, or a course of treatment for the prevention of metabolic syndrome and / or related disorders. A pharmaceutical composition containing a pharmaceutical agent (130) useful for preventing, reducing, or managing metabolic syndrome and / or related diseases is provided (121a) to a patient (100) in need thereof through a pharmacy (120). Body metric information (102c) collected from the patient during treatment is recorded (142) and stored (143) in a database (103). A medical professional (110) specializing in metabolic syndrome and related diseases monitors (112) the patient's (100) body metric information (102c) data and evaluates the patient's health condition. Adjust or maintain a course of treatment for the metabolic syndrome and / or related disorders from which the patient is suffering, or for the prevention of the metabolic syndrome and / or related disorders (113).

[0025] In another embodiment, a useful method for the measurement, diagnosis, treatment, and management of metabolic syndrome, comprising administering a pharmaceutical agent to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device, characterized in that the method comprises: A pharmaceutical composition containing a pharmaceutical agent (130) useful for preventing, reducing, or managing metabolic syndrome and / or related diseases is provided (121a) to a patient (100) in need thereof through a pharmacy (120). Through a pharmacy (120), consumables (140a) or support devices (140b) are provided (121b) to a patient (100) in need thereof for the prevention, mitigation, or management of metabolic syndrome and / or related diseases. One or more measuring devices (140) for measuring body metric information are connected (151) with an interactive user interface (150). The collected body metric information (102c) is measured (141), recorded (142), and stored (143) in a database (103). A medical professional (110) specializing in metabolic syndrome and related diseases monitors (112) the patient's (100) body metric information (102c) data and evaluates the patient's health condition. Adjust or maintain a course of treatment for the metabolic syndrome and / or related disorders from which the patient is suffering, or for the prevention of the metabolic syndrome and / or related disorders (113).

[0026] In another embodiment, a useful method for the measurement, diagnosis, treatment, and management of metabolic syndrome, comprising administering a pharmaceutical agent to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases by using an electronic device, characterized in that the method comprises: A pharmaceutical composition including a pharmaceutical agent (130) useful for preventing, mitigating, or managing metabolic syndrome and / or related disorders is provided (121a) to a patient (100) in need thereof through a pharmacy (120). An interactive user interface (150) is used to connect (151) one or more measurement devices (140) for measuring body metric information. The collected body metric information (102c) is measured (141), recorded (142), and stored (143) in a database (103). A medical professional (110) specializing in metabolic syndrome and related diseases monitors (112) the patient's (100) body metric information (102c) data and evaluates the patient's health condition. Adjust or maintain a course of treatment for the metabolic syndrome and / or related disorders from which the patient is suffering, or for the prevention of the metabolic syndrome and / or related disorders (113).

[0027] 4 illustrates an embodiment of a system for monitoring at least one body metric information for a patient (100) in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases. The system includes an electronic device and interface (160a) for entering patient identification information and / or body measurement information into a database. The device and interface (160b) for collecting and storing patient identification and / or anthropometric information in a database for incorporation into a medical record; means for accessing (170) between the patient and a medical professional specializing in metabolic syndrome and related diseases for evaluating the patient's health status; means for displaying the health status to the patient and recording it in the medical record (170a); means for instructing the patient on a course of treatment for the treatment or prevention of metabolic syndrome and / or metabolic syndrome related diseases from which the patient is suffering (170b); means for providing (121a) to a patient in need (100) a pharmaceutical composition comprising a medicament useful for the prevention, mitigation or management of metabolic syndrome and / or related diseases; means for providing consumables or support devices for the prevention, mitigation or management of metabolic syndrome and / or related diseases to a patient in need (100). means for providing (121b) to the patient; means for connecting (152) with an interactive user interface to one or more measuring devices for measuring body metric information; a database (103) for recording and storing the collected body metric information; a means for a medical professional specializing in metabolic syndrome and related diseases to monitor (112) the patient's body metric information data in order to assess the patient's health status; access means for the medical professional to adjust or maintain a treatment plan (113) for the treatment of metabolic syndrome and / or related diseases or for the prevention of metabolic syndrome and / or related diseases from which the patient suffers; and access means for establishing (114) communication between the patient and the medical professional, optionally at set time periods or upon request of the patient or the medical professional.

[0028] FIG. 5 is a diagram illustrating an embodiment of a useful method for measuring, diagnosing, treating, and managing metabolic syndrome, comprising administering a pharmaceutical agent to a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using an electronic device, characterized in that the method comprises the steps of: The present invention provides a patient and a medical professional with a therapeutic or preventive monitoring system (200), the monitoring system including at least an electronic device and interface (160a) for inputting patient identification information and / or body metric information into a database, a device and interface (160b) for collecting and storing patient identification information and / or body metric information in a database for incorporation into a medical record, a means for communication between the patient and a medical professional specializing in metabolic syndrome and related diseases, and an access (170) for evaluating the health status of the patient, a means for indicating and recording the health status of the patient in the medical record (170a), and a means for instructing the patient on a course of treatment for the metabolic syndrome and / or related diseases from which the patient is suffering, or a course of treatment for the prevention of metabolic syndrome and / or related diseases (170b), and a pharmaceutical composition comprising a pharmaceutical agent useful for the prevention, mitigation, or management of metabolic syndrome and / or related diseases, for a patient in need thereof. means for providing (121a) to a patient in need thereof; means for providing (121b) to a patient in need thereof supplies or support devices for the prevention, mitigation or management of metabolic syndrome and / or related diseases; means for connecting (152) by using an interactive user interface for one or more measuring devices for measuring body metric information; a database (103) for recording and storing the collected body metric information; means for a medical professional specializing in metabolic syndrome and related diseases to monitor (112) the data of the patient's body metric information to evaluate the patient's health status; means for the medical professional to access in order to adjust or maintain a course of treatment (113) for the treatment of the patient's metabolic syndrome and / or related diseases or for the prevention of metabolic syndrome and / or related diseases; optionally, means for establishing (114) communication between the patient and the medical professional for a set period of time or at the request of the patient or the medical professional;providing the patient (100) with a pharmaceutical composition comprising a pharmaceutical agent (130) useful for preventing, reducing or managing metabolic syndrome and / or related diseases from the patient's patient identification information and body metric information or medical records previously stored in a database;

[0029] A medical professional (110) specializing in metabolic syndrome and related diseases uses an interactive user interface connected to one or more measurement devices for measuring body metric information to monitor data of the patient's body metric information and evaluate the patient's health condition.

[0030] FIG. 6 shows a system for monitoring at least one body metric information of a patient in need thereof to prevent or reduce the risk of metabolic syndrome and related diseases using a measuring device and associated electronic device for measuring body metric information, characterized in that it includes: a patient monitoring module mounted in a patient electronic device and interface (160a), at least one measuring device (140) for measuring body metric information connectable to the patient electronic device and interface (160a), and a means of communication (180) between the patient electronic device and interface (160a) and the measuring device for measuring body metric information, the patient monitoring module (i) collecting (101) patient identification information (102a) and / or body metric information (102c), (ii) recording (142) and storing (143) the measured (141) body metric information (102c) of the patient in a database (103), and (iii) storing said information in the database (103) for incorporation into a medical record (102b). (iv) referring (111) the patient (100) to a medical professional (110) who specializes in metabolic syndrome and / or related disorders, evaluating the patient's health status, providing the patient with a health status (111b), recording the status in the medical record (102b), and instructing the patient on a course of treatment (111c) for the treatment of metabolic syndrome and / or related disorders or for the prevention of metabolic syndrome and / or related disorders. (v) providing (121a) through the pharmacy (120) to the patient (100) in need thereof pharmaceutical compositions including drugs (130) useful for the prevention, reduction or management of metabolic syndrome and / or related disorders, as well as consumables (140a) or support devices (140b). (vi) establishing a connection (151) with at least one measuring device (140) for measuring body metric information. (vii) Measuring (141), recording (142), and storing (143) body metric information (102c) in a database (103).(viii) measuring (141), recording (142) and storing (143) in a database (103) body metric information (102c) obtained from at least one measuring device (140) for measuring body metric information, (vii) allowing a medical professional (110) specializing in metabolic syndrome and related diseases to access (170) the patient's medical records in order to evaluate the patient's health status and adjust or maintain the course of treatment (113), and optionally (ix) establishing (114) communication between the patient (100) and the medical professional (110) at set time periods or upon request of the patient or the medical professional.

[0031] FIG. 7 shows a connectivity model of a monitoring system linking at least one body metric information to a patient (100) in need of a pharmaceutical composition comprising a pharmaceutical product (130) useful for preventing, reducing, or managing metabolic syndrome and / or related diseases, using an electronic device associated with a measuring device (140) for measuring the body metric information, the system including a user interface, communication means, and a database.

[0032] The patient, healthcare professional or third party authorized to access the information stored in the interface or database can visualize the body metric information through the interface, as well as patient information and records. This information is provided to the patient or authorized third party to indicate the normal range of measurements, to indicate if there are risk factors that should be addressed, and to indicate the achieved progress of the treatment, allowing both the patient and the healthcare professional or third party authorized to monitor to take prompt action to achieve the goals of the treatment.

[0033] The electronic device and interface (160a) for entering patient identification information and / or body metric information into the database, and the device and interface (160b) for collecting patient identification information and / or body metric information and storing it in the database and incorporating it into the medical record, may be a laptop or desktop computer, an electronic tablet, a smart display, a smart screen, a smart mobile phone, a video game console, a media player device, a smart watch, a smart bracelet, or any device that allows data to be entered by text, voice, or some other encoding and that can be connected by wire or wirelessly.

[0034] In a non-limiting embodiment, the referral (111) of the patient (100) to a medical professional (110) specializing in metabolic syndrome and related disorders is performed by video call using an electronic device with pre-identification of the patient and medical professional to assess the patient's health status. Once the link is established, medical paperwork is performed and all information from the patient's file or in situ measurements using a measuring device that measures body metric information is integrated to obtain a doctor's treatment course of treatment and a dispensing order to provide a pharmaceutical composition including a drug useful for preventing, reducing, or managing metabolic syndrome and / or related disorders.

[0035] Patient and medical personnel identification may be accomplished through a number of embodiments, such as a password, identification number, username, or biometric authentication (fingerprint, retina, or facial identification), identification card, or other means of identification.

[0036] A user interface for both the patient and the medical personnel can be connected to one or more screens, printers, speakers, and / or other devices for operation. The interface can include notifications, links, buttons, tabs, checkboxes, bullets, text fields, drop boxes, etc., and can provide a variety of outputs in response to user input, such as text, still images, video, audio, and animation.

[0037] The connection may be selected from a local area network, a wireless local area network, a tree or ring topography network, a wireless Internet point of presence system, Ethernet, Internet, wireless communication, infrared, fiber optics, 2G, 3G, 4G, or 5G data telephony.

[0038] Pharmaceutical compositions containing useful pharmaceutical agents (130) for preventing, reducing, or managing metabolic syndrome and / or related disorders include pharmaceutical agents for preventing, reducing, or managing overweight, obesity, hyperglycemia (type I or type II diabetes), hypertension, heart disease, dyslipidemia, and other related disorders.

[0039] In a preferred embodiment, the pharmaceutical composition comprising a useful medicament (130) for the prevention, reduction, or management of metabolic syndrome and / or related diseases is a formulation for the prevention, reduction, or management of overweight and obesity, comprising a chemical uncoupler of oxidative phosphorylation, tyrphostin AG17, orlistat, L-carnitine, benzphetamine, phendimetrazine, diethylpropion, liraglutide, naltrexone, phentermine, topiramer. , glibenclamide, metformin, acarbose, canagliflozin, dapagliflozin, saxagliptin, dulaglutide, empagliflozin, exenatide, lixisenatide, semaglutide, CBD, sibutramine, hydroxycitric acid, coenzyme q10, chromium picolinate, gamma-linolenic acid, resveratrol, omega-3 fatty acids, antioxidants, vitamins, vitamin B, vitamin C, adrenal extract, pantothenic acid, turmeric longa, Bayberry bark, Myrica cerifera, Oryza sativa L. indica, Camellia sinensis, Theobroma cacao, Emblica officinalis, Ilex paraguariensis, Cascara sagrada bark, Rhamnus purshiana, Acacia nilotica, Persimmon, Blueberry leaf, Grape seed, Cordia salicifolia, Hypericum perforatum, Pueruria thomsonn, Capers spinosa), Gymnema sylvestre, Elderberry, Sambicus, Citrus aurantium, Coffea canefora, Sygium cumini,Rosemary (Rosmarinus officinalis), Ginger (Zingiber officinalis), Cassia nomame, Cissus quadrangularis, Phaseolus vulgaris, Licorice Root, Fenugreek, Yohimbe, White willow, Cordyceps sinensis, Ashwaganda, Astragalus, Gingseng, Schisandra, Siberian gingseng, Asian gingseng, Guggul, Gagal, Mukul, Momordica charantia, Garcinia cambogia, Marshmallow (Althaea officinalis), Bougainvillea spectabilis, Medicago sativa, Valeriana officinalis, Damiana, Sambucus nigra), Capsicum spp., Allium spp., calcium myristate, magnesium myristate, tetradecylthioacetic acid (TTA), thyroid hormones or precursors thereof, thyrotropic agents, Kreb cycle metabolites, UCP-1, UCP-2, UCP-3, endogenous uncoupling protein or precursors of PUMP (plant uncoupling mitochondrial protein), agonists or enhancers, leucine, valine, isoleucine, glutamine, proline, tyrosine, conjugated linoleic acid, adrenergic secretagogues, fatty acids or esters, beta agonists, glucagon, arbutamine, vasopressin, ubiquinone, coenzyme Q1, coenzyme Q2, melatonin, fatty acid esters of estrogens such as oleylestrone, glucomannan, menthol, peppermint essential oil, thyme essential oil, elemental sulfur and policosanol, insulin or insulin analogues,and oral hypoglycemic agents; acetohexamide, carbutamide, chlorpropamide, glibenclamide, glibornuride, gliclazide, glimepiride, glipizide, tolazamide, tolbutamide, (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3, 4, 5-triol or Glyset)(1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)-cyclohexane-1,2,3,4-tetraol), (RS)-5-[4-(2-[methyl (pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione, (RS)-5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)thiazolidine-2,4-dione, 5-[(4-[2-([6-(4-methoxyphenoxyl)pyrimidin-4-yl]-methylamino)ethoxy]phenyl-methyl]-1,3-thiazolidine-2,4-dione, (RS)-5-(4-[( 6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy)benzyl)thiazolidine-2,4-dione, (S)-(+)-2-ethoxy-4-[2-(3-methyl-1-[2-(piperidin-1-yl)phenyl]butylamino)-2-oxoethyl]benzoic acid, 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid, (2S)-2-benzyl-4- [(3aR,7aS)-Octahydro-2H-isoindol-2-yl]-4-oxobutanoic acid, L-ornithine, L-tyrosine, L-tryptophan, L-phenylalanine, conjugated linoleic acid, gamma-linolenic acid, chromium picolinate, glucose tolerance factor, vanadyl sulfate, Gymnema sylvestre, bromelain, pancreatin, Pagymnema sylvestre 10, curcumin, barberry, bearberry, silymarin, Drosophila melanogaster D, choline, inositol, human growth hormone, DHEA (e.g., fucoxanthin), caffeine, xanthenes, cola nut, psyllium, yerba mate, guarana, ginseng, medium-chain triglycerides, hydroxycitric acid (HCA), kelp, lecithin, dihydroxyacetone, pyruvic acid, creatine, iodine, niacin, bladderwrack, white kidney bean extract, glucomannan, chitosan, resveratrol,Resveratrol derivative, Vitamin D, hCG, Capsaicin, Chia, Hoodia, Apple Cider Vinegar, Coconut Oil, Bitter Orange, B Vitamins, Fluoxetine, Chitosan, Chromium Picolinate, Conjugated Linoleic Acid (CLA), Glucomannan, Green Tea Extract, Green Tea Extract, Guar Gum, Hoodia, 7-Keto-DHEA, DHEA, Ephedra, Bitter Orange, Turmetic, Ginger, Root Powder, Apple Cider Vinegar, Calcium, Hesperidin, Apanthenol Gynostemma, Flaxseed Oil, Orange Peel Powder, Thiamine, Ashwagandha Extract, Coffee Extract, L-Theanine, Heavy Alcohol Choline nitrate, red mango extract, white kidney bean extract, C. cinephora robusta extract, acetyl-L carnitine, Garcinia cambogia, cumbusia extract, coconut oil, forskolin extract, black pepper extract, seroxat, citalopram, bupropion, topiramate, ecopipam, naltrexone, peptide YY3-36, leptin, exemphetamine, amphetamine, phentermine, mazindol phendimetrazine, diethylpropion, fenfluramine, dexfenfluramine, pharmaceutically acceptable salts and derivatives thereof and mixtures thereof.

[0040] In another embodiment, the pharmaceutical composition containing the pharmaceutical agent (130) useful for the prevention, alleviation, or management of metabolic syndrome and / or related diseases is selected from the group consisting of chemical uncouplers of oxidative phosphorylation, biguanides, imidazolines, α-glucosidase inhibitors, meglitinidas, oxadiazolidinediones, thiazolidinediones, insulin sensitizers, sulfonylureas, potassium channel blockers such as nateglinide or BTS-67582, glucagon antagonists, inhibitors of DPP-IV (dipeptidyl peptidase-IV), inhibitors of PTPasa (protein tyrosine phosphatase), glucokinase activators, enzymes and metabolites involved in the regulation of gluconeogenesis or glycogenolysis, glucose uptake modulators, GSK-3 (glycogen synthase kinase-3) inhibitors, compounds that modify lipid metabolism such as hyperlipidemic therapeutics, antilipidemic therapeutics, compounds that reduce food intake, PPAR agonists; e.g., tyrphostin AG, Tyrphostin A9, insulin and insulin analogues, tolbutamide, chlorpropamide, tolazamide, glibenclamide, glipizide, glimepiride, glicazide / glyburide, metformin, repaglinide or senaglinide / nateglinide, troglitazone, pioglitazone, rosiglitazone, isaglitazone, darglitazone, englitazone, GI262570, YM-440, MCC-555, JTT-501, AR-H039242, KRP- 297, GW-409544, CRE-16336, AR-H, voglibose, emiglitate, miglitol / acarbose, tolbutamide, glibenclamide, glipizide, glicazide, BTS-67582o repaglinide, nateglinide, cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, pharma- ceutically acceptable salts and derivatives thereof, and mixtures thereof.

[0041] In another embodiment, the pharmaceutical composition containing a useful pharmaceutical agent (130) for the prevention, reduction, or management of metabolic syndrome and / or related diseases comprises a pharmaceutical agent for the prevention, reduction, or management of hypertension selected from the following: alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and [alpha]-blockers such as doxazosin, urapidil, prazosin and terazosin, pharmaceutically acceptable salts and derivatives thereof, and mixtures thereof.

[0042] Chemical uncouplers for oxidative phosphorylation include, but are not limited to, the following compounds: 4,4-bis-(4-hydroxy-3-nitrophenyl)valeric acid, 4-methoxy-2-nitrophenol, 4-hydroxy-3-nitroacetophenone, 7-hydroxy-4-methyl-8-nitrochromen-2-one, 3-tert-butyl-5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-6-methylbenzamide, N-1-[4-cyano-3-(trifluoromethyl)phenyl]-3-methyl-2-propanediol, and N-1-[4-cyano-3-(trifluoromethyl)phenyl]-3-methyl-2-propanediol. ,5-Di-(trifluoromethyl)benzamide, N-(4-cyanophenyl)benzamide, 2'-chloro-1-hydroxy-4'-nitro-2-naphthanilide, N-(2-chloro-4-bromophenyl)-5-bromosalicylanilide, N-(2-chloro-4-nitrophenyl)-3-tert-butyl-6-methylsalicylanilide, (3,5-di-tert-butyl-4-hydroxybenzyl)triphenylphosphonium bromide, 3,5-di-tert-butyl-4-hydroxybenzyl)tricyclohexylphosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)tributylphosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)trioctylphosphonium bromide, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylic acid ethyl ester, 2-(3,5-di-tert-butyl-4-hydroxybenzylidene)malonic acid diethyl ester, 2-amino-S-[(3,5-di-tert-butyl-4-hydroxybenzylidene)-amino]but-2-ene 2-(3,5-di-tert-butyl-4-hydroxybenzylidene)-indan-1,3-dione, 2-malononitrile, 2-(4-chlorophenyl)-indole, N-(2,4,5-trichlorophenyl)salicylanilide, 2,3-dimethyl-5-cyano-7-ethylindole, 4-bromo-2-(4-chlorophenyl)-5-trifluoromethyl-1H-pyrrole-3-carbonitrile, N-(5,7-dimethyl-1H-indol-3-ylmethylene)-3-trifluoromethyl-benzamide, 2,4-Dinitrophenol, carbonyl cyanide-p-trifluoromethoxy-phenylhydrazone, 2-(5-bromo-1H-indol-3-ylmethylene)-malononitrile, 2-((5-chloro-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-(2-phenyl-3-indolylmethylene)malononitrile 2-(2-chloro-1H-indol-3-ylmethylene)malononitrile, 2-(5-nitro-1H-indol-3-ylmethylene)malononitrile, 2-(2-methyl-5-nitro-1H-indol-3-ylmethylene)malononitrile, 3-bromo-5-tert-butyl-N-(2-chloro-4-nitrophenyl)-6-hydroxy-2-methylbenzamide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-3-isopropylbenzamide amide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-3-isopropyl-6-methylbenzamide, 3,5-di-tert-butyl-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide, 3-bromo-N-(2-chloro-4-nitrophenyl)-6-hydroxy-5-isopropyl-2-methylbenzamide, 3-tert-butyl-5-chloro-N-(4-chloro-3-trifluoromethylphenyl)-2-hydroxy-6-methyl-benzamide amide, 3-tert-butyl-5-chloro-N-(4-cyano-3-trifluoromethylphenyl)-2-hydroxy-6-methylbenzamide, 2-hydroxybiphenyl-3-carboxylic acid (2-chloro-4-nitrophenyl)-amide, 3-tert-butyl-N-(2-chloro-4-nitrophenyl)-2-hydroxy-5-methylbenzamide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-6-isopropyl-3-methylbenzamide, N-(3,5-bistrifluoromethylphenyl)-3-tert-butyl-5-chloro-2-hydroxy-6-methylbenzamide, 3-tert-butyl-5-chloro-N-(2-fluoro-5-trifluoromethylphenyl)-2-hydroxy-6-methylbenzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-3-trifluoromethylphenyl)benzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3 -Bromo-5-tert-butyl-N-(2-chloro-4-cyanophenyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(2-chloro-5-trifluoromethylphenyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methyl Benzamide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-{5-chloro-4-[(4-chlorophenyl)cyanomethyl]-2-methylphenyl}-6-hydroxy-2-methylbenzamide, 3-bromo-6-hydroxy-5-isopropyl-2-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-N- (4-nitro-2-trifluoromethylphenyl)benzamide, 3-tert-butyl-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3-bromo-N-(3,5-di-tert-butyl-4-hydroxyphenyl)-5-tert-butyl-6-hydroxy-2-methylbenzamide, N-(3,5-di-tert-butyl-4-hydroxybenzylidene)-3-bromo-5-tert-butyl-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-[(3,5-di-tert-butyl-4-hydroxybenzylidene)amino]-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-6-hydroxy-N-(4-isopropyl-2-trifluoromethylphenyl)-2-methylbenzamide, N-(3,5-di-tert-butyl-4-hydroxybenzylidene)-3-fluoro-5-trifluoromethylbenzamide, 3-fluoro-N-(4-nitro-3-trifluoromethylphenyl)-5-trifluoromethylbenzamide, N-(2,4,5 -trichlorophenyl)-3-fluoro-4-trifluoromethylbenzamide, 4-fluoro-N-(4-nitro-3-trifluoromethylphenyl)-3-trifluoromethylbenzamide, 3-(3,5-di-tert-butyl-4-hydroxyphenyl-2-(5,7-dimethyl-1H-indol-3-ylmethylene)acrylonitrile, 2-acetyl-3-(3,5-bis-trifluoromethylphenyl)acrylic acid ethyl ester, 2-(3,5-di-tert-butyl-4-hydroxybenzyl)malononyl tolyl, 2-(3,5-di-tert-butyl-4-hydroxybenzyl)malononitrile, 2,6-di-tert-butyl-4-nitrophenol, 2-tert-butyl-4,6-dinitrophenol, 3-(3,5-di-tert-butyl-4-hydroxybenzyl)-2-pyridin-2-yl-acrylonitrile, 2-(3,5-di-tert-butyl-4-hydroxyphenyl)malononitrile, 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-(diethylphosphonate)propenenitrile , 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-nitrophenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-pyridin-4-yl-acrylonitrile, 2-(3,5-bis-trifluoromethylphenyl)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-trifluoromethoxyphenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-trifluoromethyl-phenyl)acrylonitrile, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)but-2-enoic acid ethyl ester, N-(4-chlorophenyl)-2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylamide, (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-methanesulfonylacrylonitrile, (E)-2-(4-chlorobenzenesulfonyl)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-fluorobenzenesulfonyl)acrylonitrile, (E)-2-benzenesulfonyl-3- (3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, (E)-3-(3,5-bis-trifluoromethylphenyl)-2-(propane-2-sulfonyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(hexane-1-sulfonyl)acrylonitrile, 2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 2-(4-bromo-benzenesulfonyl)-3-acrylonitrile, 2-(3,5-di-tert-butyl-4-hydroxybenzylidene)acrylonitrile, 5-bromo-3-tert-butyl-N-(2-chloro-4-cyanophenyl)-2-hydroxybenzamide, 5-bromo-3-tert-butyl-N-(4-cyanophenyl)-2-hydroxybenzamide, 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-N-(2-trifluoromethylphenyl)benzamide, 2-(2-bromo-1H-indol-3-ylmethylene)malononitrile, 2-(7-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, 2-(5-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, pharma- ceutically acceptable salts thereof, derivatives thereof and mixtures thereof.

[0043] The body metric information is selected from the following: weight, BMI, body fat percentage, height, muscle, water, visceral fat, bone, metabolism, protein, obesity level, body age, lean body mass, oxygenation, body oxygenation quantified in urine, vitamins and minerals, blood glucose, blood pressure, LDL cholesterol, HDL cholesterol, triglycerides, urine glucose, pedometer, heart rate, fasting blood glucose, post-load blood glucose, total cholesterol, total bilirubin, alanine transaminase, aspartate aminotransferase and / or body temperature.

[0044] Measurement devices (140) for measuring body metric information, which is information obtained when measuring clinical parameters and / or body measurement indicators, etc., may be selected from, but are not limited to, weight scales, ORP, vitamin sticks, blood glucose meters, oximeters, smart watches, smart bracelets, smart clothing, patches, tattoos, implants, hearing aids, helmets, electrodes, chest bands, pedometers, and / or medical instruments and devices for quantifying biochemical parameters. [Explanation of symbols]

[0045] 100...patient, 101...collection, 102a...patient identification information, 102b...medical record, 102c...body metric information, 103...database, 110...healthcare professional, 112...monitoring, 113...treatment policy, 120...pharmacy, 130...medicine, 140...measuring device, 150...interactive user interface.

Claims

1. 1. A computer-implemented method for providing care to a patient (100) in need of care for metabolic syndrome and / or related disorders using an electronic device, comprising the steps of: (a) collecting (101) patient identification information (102a) and / or body metric information (102c) and storing it in a database (103) for incorporation into the clinical record (102b); (b) referring (111) said patient (100) to a medical professional (110) specializing in metabolic syndrome and related disorders for a health status evaluation; (c) indicating said health condition (111b) to said patient and recording it in a medical record (102b); (d) instructing the patient (111c) on a course of treatment for metabolic syndrome and / or related disorders or prevention of metabolic syndrome and / or related disorders; (e) providing (121a) through a pharmacy (120) to said patient (100) in need thereof a pharmaceutical composition comprising a pharmaceutical agent (130) useful for the prevention, mitigation, or management of metabolic syndrome and / or related disorders; (f) providing (121b) through said pharmacy (120) to said patient (100) in need thereof consumables (140a) or support devices (140b) for the prevention, mitigation, or management of metabolic syndrome and / or related diseases; (g) connecting (151) using an interactive user interface (150) one or more measurement devices (140) for measuring said body metric information; (h) measuring (141), recording (142) and storing (143) the collected body metric information (102c) in a database (103); (i) a medical professional (110) specializing in metabolic syndrome and / or related diseases monitoring (112) the body metric information (102c) data of the patient (100) for the purpose of assessing health status; (j) adjusting or maintaining said therapeutic regimen (113) for the treatment of metabolic syndrome and / or related disorders or for the prevention of metabolic syndrome and / or related disorders; and (k) optionally, the medical professional (110) providing assistance (114) to the patient (100) at defined time periods or upon request of the patient or medical professional.

2. 2. The computer-implemented method of providing care to the patient (100), wherein the body metric information is selected from weight, BMI, percent body fat, height, muscle, water, visceral fat, bone, metabolism, protein, obesity index, body age, lean body mass, oxygenation, body oxygenation quantified in urine, vitamins and minerals, blood glucose, blood pressure, LDL cholesterol, HDL cholesterol, triglycerides, urine glucose, pedometer, heart rate, fasting blood glucose, post-load blood glucose, total cholesterol, total bilirubin, alanine transaminase, aspartate aminotransferase, and body temperature.

3. 3. The computer-implemented method for providing care to the patient (100), according to claim 1 or 2, wherein the measuring device (140) is selected from a weighing scale, ORP, vitamin stick, blood glucose meter, oximeter, smart watch, smart bracelet, smart clothing, patch, tattoo, implant, hearing aid, helmet, electrode, chest strap, pedometer, medical equipment for quantification of biochemical parameters.

4. A computer-implemented method for providing care to the patient (100), wherein the pharmaceutical composition comprising the pharmaceutical agent (130) useful for preventing, alleviating, or managing metabolic syndrome and / or related disorders is selected from the group consisting of tyrphostin AG17, chemical uncouplers of oxidative phosphorylation, orlistat, L-carnitine, benzphetamine, phendimetrazine, diethylpropion, liraglutide, naltrexone, phentermine, topiramate, glybenzyl benzoate, phentermine ... Inclamide, metformin, acarbose, canagliflozin, dapagliflozin, saxagliptin, dulaglutide, empagliflozin, exenatide, lixisenatide, semaglutide, CBD, sibutramine, hydroxycitric acid, coenzyme q10, chromium picolinate, gamma-linolenic acid, resveratrol, omega-3 fatty acids, antioxidants, vitamins, vitamin B, vitamin C, adrenal extract, pantothenic acid, turmeric longa), white bayberry bark, white bayberry (Myrica cerifera), indica rice (Oryza sativa L. indica), tea plant (Camellia sinensis), cacao (Theobroma cacao), amla (Emblica officinalis), yerba mate (Ilex paraguariensis), Cascara sagrada bark, Cascara sagrada (Rhamnus purshiana), Acacia nilotica, persimmon, blueberry leaf leaf), grape seed, Cha de bougre (Cordia salicifolia), St. John's wort (Hypericum perforatum), Pururia thomsonn, capers (Capparis spinosa), garden vine (Gymnema sylvestre), elderberry, Sambicus, bitter orange (Citrus aurantium), robusta coffee tree (Coffea canefora), purple myrtle (Sygium)cumini), rosemary (Rosmarinus officinalis), ginger (Zingiber officinalis), Cassia noma, Cissus quadrangularis, kidney bean (Phaseolus vulgaris), licorice root, fenugreek, yohimbine, white willow, cordyceps sinensis), Ashwagandha, Astragalus, Gingseng, Schisandra, Siberian ginseng, Asian ginseng, Guggul, Gagal, Mukul, Commiphora mukul, Momordica charantia, Garcinia cambogia, Marshmallow, Althaea officinalis, Bougainvillea spectabilis, Medicago sativa sativa), Valeriana officinalis, Damiana, Sambucus nigra, Capsicum, Allium, Calcium myristate, Magnesium myristate, Tetradecylthioacetic acid(TTA), thyroid hormones or precursors thereof, thyroid stimulants, Kreb cycle metabolites, UCP-1, UCP-2, UCP-3, endogenous uncoupling protein of PUMP (plant uncoupling mitochondrial protein) or precursors thereof, agonists or enhancers, leucine, valine, isoleucine, glutamine, proline, tyrosine, conjugated linoleic acid, adrenergic secretagogues, fatty acids or esters, beta agonists, glucagon, albuterol, vasopressin, ubiquinone, coenzyme Q1, coenzyme Q2, melatonin, fatty acid esters of estrogen, glucomannan, menthol, peppermint essential oil, thyme essential oil , elemental sulfur and policosanol, insulin or insulin analogs, acetohexamide, carbutamide, chlorpropamide, glibenclamide, glibornuride, gliclazide, glimepiride, glipizide, tolazamide, tolbutamide, (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol or Glyset)(1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)-cyclohexane-1,2,3,4-tetraol), (RS)-5-[4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione, (RS)-5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)thiazolidine-2,4-dione, 5-[(4-[2-([6-(4-methoxyphenoxy)pyrimidin-4-yl]-methylamino)ethoxy]phenylmethyl]-1,3-thiazolidine-2,4-dione, (RS)-5-(4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl ) methoxy) benzyl) thiazolidine-2,4-dione, (S)-(+)-2-ethoxy-4-[2-(3-methyl-1-[2-(piperidin-1-yl)phenyl]butylamino)-2-oxoethyl]benzoic acid, 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid, (2S)-2-benzyl-4-[(3aR,7aS)-octahydro-2H-isoindol-2-yl]-4-oxobutanoic acid, L-ornithine, L-tyrosine, L-tryptophan, L-phenylalanine, conjugated linoleic acid, gamma-linolenic acid, chromium picolinate, glucose tolerance factor, vanadyl sulfate, gymnema sylvestre, bromelain, pancreatin, gymnema sylvestre 10, curcumin, barberry, bearberry, silymarin, fruit fly, choline, inositol, human growth hormone, DHEA, fucoxanthin, caffeine, xanthenes, cola nut, psyllium syrup, yerba mate, guarana, ginseng, medium-chain triglycerides, hydroxybenzoates 4. The method of claim 1, wherein the active ingredient is selected from the group consisting of citric acid (HCA), kelp, lecithin, dihydroxyacetone, pyruvic acid, creatine, iodine, niacin, bladderwrack, white kidney bean extract, glucomannan, chitosan, resveratrol, resveratrol derivatives, vitamin D, hCG, capsaicin, chia, hoodia, apple cider vinegar, coconut oil, bitter orange, B vitamins, pharmaceutically acceptable salts and derivatives thereof, and combinations thereof.

5. 1. A computer-implemented method for providing care to the patient (100), wherein the chemical uncoupler of oxidative phosphorylation is selected from the group consisting of 4,4-bis-(4-hydroxy-3-nitrophenyl)valeric acid, 4-methoxy-2-nitrophenol, 4-hydroxy-3-nitroacetophenone, 7-hydroxy-4-methyl-8-nitrochromen-2-one, 3-tert-butyl-5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-6-methylbenzamide, N-1-[4-cyano-3-(trifluoromethyl)phenyl] -3,5-di-(trifluoromethyl)benzamide, N-(4-cyanophenyl)benzamide, 2'-chloro-1-hydroxy-4'-nitro-2-naphthanilide, N-(2-chloro-4-bromophenyl)-5-bromosalicylanilide, N-(2-chloro-4-nitrophenyl)-3-tert-butyl-6-methylsalicylanilide, (3,5-di-tert-butyl-4-hydroxybenzyl)triphenylphosphonium bromide, 3,5-di-tert-butyl-4-hydroxybenzyl)tricyclohexylphosphonium phosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)tributylphosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)trioctylphosphonium bromide, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylic acid ethyl ester, 2-(3,5-di-tert-butyl-4-hydroxybenzylidene)malonic acid diethyl ester, 2-amino-S-[(3,5-di-tert-butyl-1-4-hydroxybenzylidene)-amino]but-2- Enedinitrile, 2-(3,5-di-tert-butyl-4-hydroxybenzylidene)-indan-1,3-dione, 2-malononitrile, 2-(4-chlorophenyl)-indole, N-(2,4,5-trichlorophenyl)salicylanilide, 2,3-dimethyl-5-cyano-7-ethylindole, 4-bromo-2-(4-chlorophenyl)-5-trifluoromethyl-1H-pyrrole-3-carbonitrile, N-(5,7-dimethyl-1H-indol-3-ylmethylene)-3-trifluoromethyl-benzamide, 2,4-Dinitrophenol, carbonyl cyanide-p-trifluoromethoxy-phenylhydrazone, 2-(5-bromo-1H-indol-3-ylmethylene)-malononitrile, 2-((5-chloro-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-(2-phenyl-3-indolylmethylene) Malononitrile, 2-(2-chloro-1H-indol-3-ylmethylene)malononitrile, 2-(5-nitro-1H-indol-3-ylmethylene)malononitrile, 2-(2-methyl-5-nitro-1H-indol-3-ylmethylene)malononitrile, 3-bromo-5-tert-butyl-N-(2-chloro-4-nitrophenyl)-6-hydroxy-2-methylbenzamide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-3-isopropylbenzamide Amide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-3-isopropyl-6-methylbenzamide, 3,5-di-tert-butyl-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide, 3-bromo-N-(2-chloro-4-nitrophenyl)-6-hydroxy-5-isopropyl-2-methylbenzamide, 3-tert-butyl-5-chloro-N-(4-chloro-3-trifluoromethylphenyl)-2-hydroxy-6-methylbenzamide benzamide, 3-tert-butyl-5-chloro-N-(4-cyano-3-trifluoromethylphenyl)-2-hydroxy-6-methylbenzamide, 2-hydroxybiphenyl-3-carboxylic acid (2-chloro-4-nitrophenyl)-amide, 3-tert-butyl-N-(2-chloro-4-nitrophenyl)-2-hydroxy-5-methylbenzamide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-6-isopropyl-3-methylbenzamide, N-(3,5-bistrifluoromethylphenyl)-3-tert-butyl-5-chloro-2-hydroxy-6-methylbenzamide, 3-tert-butyl-5-chloro-N-(2-fluoro-5-trifluoromethylphenyl)-2-hydroxy-6-methylbenzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-3-trifluoromethylphenyl)benzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3 -bromo-5-tert-butyl-N-(2-chloro-4-cyanophenyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(2-chloro-5-trifluoromethylphenyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methyl benzamide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-{5-chloro-4-[(4-chlorophenyl)cyanomethyl]-2-methylphenyl}-6-hydroxy-2-methylbenzamide, 3-bromo-6-hydroxy-5-isopropyl-2-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-N- (4-nitro-2-trifluoromethylphenyl)benzamide, 3-tert-butyl-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3-bromo-N-(3,5-di-tert-butyl-4-hydroxyphenyl)-5-tert-butyl-6-hydroxy-2-methylbenzamide, N-(3,5-di-tert-butyl-4-hydroxybenzylidene)-3-bromo-5-tert-butyl-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-[(3,5-di-tert-butyl-4-hydroxybenzylidene)amino]-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-6-hydroxy-N-(4-isopropyl-2-trifluoromethylphenyl)-2-methylbenzamide, N-(3,5-di-tert-butyl-4-hydroxybenzylidene)-3-fluoro-5-trifluoromethylbenzamide, 3-fluoro-N-(4-nitro-3-trifluoromethylphenyl)-5-trifluoromethylbenzamide, N-(2,4,5 -trichlorophenyl)-3-fluoro-4-trifluoromethylbenzamide, 4-fluoro-N-(4-nitro-3-trifluoromethylphenyl)-3-trifluoromethylbenzamide, 3-(3,5-di-tert-butyl-4-hydroxyphenyl-2-(5,7-dimethyl-1H-indol-3-ylmethylene)acrylonitrile, 2-acetyl-3-(3,5-bis-trifluoromethylphenyl)acrylic acid ethyl ester, 2-(3,5-di-tert-butyl-4-hydroxybenzyl)malononyl tolyl, 2-(3,5-di-tert-butyl-4-hydroxybenzyl)malononitrile, 2,6-di-tert-butyl-4-nitrophenol, 2-tert-butyl-4,6-dinitrophenol, 3-(3,5-di-tert-butyl-4-hydroxybenzyl)-2-pyridin-2-yl-acrylonitrile, 2-(3,5-di-tert-butyl-4-hydroxyphenyl)malononitrile, 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-(diethylphosphonate)propenenitrile , 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-nitrophenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-pyridin-4-yl-acrylonitrile, 2-(3,5-bis-trifluoromethylphenyl)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-trifluoromethoxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-trifluoromethylphenyl)acrylonitrile, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)but-2-enoic acid ethyl ester, N-(4-chlorophenyl)-2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylamide, (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-methanesulfonylacrylonitrile, (E)-2-(4-chlorobenzenesulfonyl)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-fluorobenzenesulfonyl)acrylonitrile, (E)-2-benzenesulfonyl-3- (3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, (E)-3-(3,5-bis-trifluoromethylphenyl)-2-(propane-2-sulfonyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(hexane-1-sulfonyl)acrylonitrile, 2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 2-(4-bromo-benzenesulfonyl)-3-acrylonitrile, 2-(3,The method according to claim 4, wherein the compound is selected from the group consisting of 5-di-tert-butyl-4-hydroxybenzylidene)acrylonitrile, 5-bromo-3-tert-butyl-N-(2-chloro-4-cyanophenyl)-2-hydroxybenzamide, 5-bromo-3-tert-butyl-N-(4-cyanophenyl)-2-hydroxybenzamide, 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-N-(2-trifluoromethylphenyl)benzamide, 2-(2-bromo-1H-indol-3-ylmethylene)malononitrile, 2-(7-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, 2-(5-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, pharmaceutically acceptable salts thereof, derivatives thereof, and combinations thereof.

6. 10. A computer-implemented method for providing care to the patient (100) of claim 1, wherein the associated disorders of metabolic syndrome are hypertension, hyperglycemia (in the form of type 1 diabetes or type 2 diabetes), overweight or obesity, or a combination thereof.

7. 7. The method of claim 6, wherein the metabolic syndrome-related disease is hypertension, and the pharmaceutical composition comprising the pharmaceutical agent (130) is a pharmaceutical agent for the prevention, alleviation, or management of hypertension, and the pharmaceutical agent is selected from ACE (angiotensin-converting enzyme) inhibitors including alprenolol, atenolol, timolol, pindolol, propranolol, and metoprolol, benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril, and ramipril, calcium channel blockers including nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem, and verapamil, and alpha-blockers including doxazosin, urapidil, prazosin, and terazosin, and pharmaceutically acceptable salts and derivatives thereof, and mixtures thereof.

8. A computer-implemented method for providing care to the patient (100), wherein when a metabolic syndrome-related disorder is hyperglycemia, the pharmaceutical composition comprising the medication (130) is a medication for the prevention, reduction, or management of hyperglycemia, and the pharmaceutical composition is selected from the group consisting of tyrphostin AG, tyrphostin A9, insulin and insulin analogs, tolbutamide, chlorpropamide, tolazamide, glibenclamide, glipizide, glimepiride, glicazide / glyburide, metformin, repaglinide, senaglinide, nateglinide, thrombin ... Roglitazone, pioglitazone, rosiglitazone, isaglitazone, darglitazone, englitazone, GI262570, YM-440, MCC-555, JTT-501, AR-H039242, KRP-297, GW-409544, CRE-16336, AR-H, voglibose, emiglitate, miglitol / acarbose, tolbutamide, glibenclamide, glipizide, glicazide, BTS-67582, repaglinide, nateglinide, cholestyramine, colestipol, clofibrate, gemfibrozide drugs acting on the ATP-dependent potassium channel of pancreatic [β] cells, biguanides, imidazolines, [α]-glucosidase inhibitors, meglitinides, oxadiazolidinediones, thiazolidinediones, insulin sensitizers, sulfonylureas, potassium channel blockers such as nateglinide or BTS-67582, glucagon antagonists, DPP-IV (dipeptidyl peptidase IV) 7. The method of claim 6, wherein the active ingredient is selected from the group consisting of lipid metabolism modifying compounds such as glutathione-4 (GTP-IV) inhibitors, PTPase (protein tyrosine phosphatase) inhibitors, glucokinase activators, inhibitors of hepatic enzymes involved in stimulating gluconeogenesis and / or glycogenolysis, glucose uptake regulators, GSK-3 (glycogen synthase kinase-3) inhibitors, compounds that modify lipid metabolism such as antihyperlipidemic agents and antilipidemic agents, compounds that reduce food intake and PPAR agonists, and pharmaceutically acceptable salts and derivatives thereof, and mixtures thereof.

9. A computer-implemented method for providing care to the patient (100), wherein the disorder associated with metabolic syndrome is overweight or obesity, and the pharmaceutical composition comprising the pharmaceutical agent (130) useful for preventing, reducing, or managing overweight and obesity includes tyrphostin AG17, a chemical uncoupler of oxidative phosphorylation, orlistat, L-carnitine, benzphetamine, phendimetrazine, diethylpropion, liraglutide, naltrexone, phentermine, Topiramate, glibenclamide, metformin, acarbose, canagliflozin, dapagliflozin, saxagliptin, dulaglutide, empagliflozin, exenatide, lixisenatide, semaglutide, CBD, sibutramine, hydroxycitric acid, coenzyme Q10, chromium picolinate, gamma-linolenic acid, resveratrol, omega-3 fatty acids, antioxidants, vitamins, vitamin B, vitamin C, adrenal extract, pantothenic acid, turmeric longa), white bayberry bark, white bayberry (Myrica cerifera), indica rice (Oryza sativa L. indica), tea plant (Camellia sinensis), cacao (Theobroma cacao), amla (Emblica officinalis), yerba mate (Ilex paraguariensis), Cascara sagrada bark, Cascara sagrada (Rhamnus purshiana), Acacia nilotica, persimmon, blueberry leaf leaf), grape seed, Cha de bougre (Cordia salicifolia), St. John's wort (Hypericum perforatum), Pururia thomsonn, capers (Capparis spinosa), garden vine (Gymnema sylvestre), elderberry, Sambicus, bitter orange (Citrus aurantium), robusta coffee tree (Coffea canefora), purple myrtle (Sygium)cumini), rosemary (Rosmarinus officinalis), ginger (Zingiber officinalis), Cassia nomame), Cissus quadrangularis, Phaseolus vulgaris, Licorice root, Fenugreek, Yohimbine, White willow, Cordyceps sinensis, Ashwagandha, Astragalus, Gingseng, Schisandra, Siberian ginseng, Asian ginseng, Guggul mukul Commiphora mukul, Momordica charantia, Garcinia cambogia, Marshmallow (Althaea officinalis), Bougainvillea spectabilis, Medicago sativa, Valeriana officinalis, Damiana, Sambucus nigra), Capsicum, Allium, calcium myristate, magnesium myristate, tetradecylthioacetic acid (TTA), thyroid hormones or precursors thereof, thyroid-stimulating agents, Kreb cycle metabolites, UCP-1, UCP-2, UCP-3, endogenous uncoupling proteins of PUMP (plant uncoupling mitochondrial protein) or precursors thereof, agonists or enhancers, leucine, valine, isoleucine, glutamine, proline, tyrosine, conjugated linoleic acid, adrenergic agents, fatty acids or esters, beta-agonists, glucagon, albutamine, vasopressin, ubiquinone, coenzyme Q1, coenzyme Q2, melatonin, fatty acid esters of estrogen, glucomannan, menthol, peppermint oil, thyme oil, elemental sulfur and policosanol, insulin or insulin analogues, acetohexamide, carbutamide, chlorpropamide, glibenclamide, glibornuride, gliclazide, glimepiride, glipizide, tolazamide, tolbutamide, (2R, 3R, 4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol or Glyset)(1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)-cyclohexane-1,2,3,4-tetraol), (RS)-5-[4-(2-[methyl (pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione, (RS)-5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)thiazolidine-2,4-dione, 5-[(4-[2-([6-(4-methoxyphenoxy)pyrimidin-4-yl]-methylamino)ethoxy]phenylmethyl]-1,3-thiazolidine-2,4-dione, (RS)-5-(4-[(6-hydroxypyridin-2-yl)amino]ethoxy)benzyl)thiazolidine-2,4-dione (2S)-2-benzyl-4-[(3-methyl-1-[2-(piperidin-1-yl)phenyl]butylamino]-2-oxoethyl]benzoic acid, 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid, (2S)-2-benzyl-4-[(3aR,7aS)-octahydro-2H-isoindol-2-yl]-4-oxobutanoic acid, L-ornithine, L-tyrosine, L-tryptophan, L-phenylalanine, conjugated linoleic acid, gamma-linolenic acid, chromium picolinate, glucose tolerance factor, vanadyl sulfate, Gymnema sylvestre, bromelain, pancreatin, Pagymnema sylvestre 10, curcumin, barberry, bearberry, silymarin, Drosophila melanogaster, choline, inositol, human growth hormone, DHEA, fucoxanthin, caffeine, xanthenes, cola nut, osmanthus 7. The method of claim 6, wherein the active ingredient is selected from the group consisting of ko, yerba mate, guarana, ginseng, medium-chain triglycerides, hydroxycitric acid (HCA), kelp, lecithin, dihydroxyacetone, pyruvic acid, creatine, iodine, niacin, bladderwrack, white kidney bean extract, glucomannan, chitosan, resveratrol, resveratrol derivatives, vitamin D, hCG, capsaicin, chia, hoodia, apple cider vinegar, coconut oil, bitter orange, B vitamins, pharmaceutically acceptable salts and derivatives thereof, and combinations thereof.

10. A computer-implemented method for providing care to the patient (100), wherein the chemical uncoupler of oxidative phosphorylation is selected from the group consisting of 4,4-bis-(4-hydroxy-3-nitrophenyl)valeric acid, 4-methoxy-2-nitrophenol, 4-hydroxy-3-nitroacetophenone, 7-hydroxy-4-methyl-8-nitrochromen-2-one, 3-tert-butyl-5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-6-methylbenzamide, N-1-[4-cyano-3-(trifluoromethyl)phenyl]-2-methyl-2-propanol, N ... ]-3,5-di-(trifluoromethyl)benzamide, N-(4-cyanophenyl)benzamide, 2'-chloro-1-hydroxy-4'-nitro-2-naphthanilide, N-(2-chloro-4-bromophenyl)-5-bromosalicylanilide, N-(2-chloro-4-nitrophenyl)-3-tert-butyl-6-methylsalicylanilide, (3,5-di-tert-butyl-4-hydroxybenzyl)triphenylphosphonium bromide, 3,5-di-tert-butyl-4-hydroxybenzyl)tricyclohexylphos phosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)tributylphosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)trioctylphosphonium bromide, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylic acid ethyl ester, 2-(3,5-di-tert-butyl-4-hydroxybenzylidene)malonic acid diethyl ester, 2-amino-S-[(3,5-di-tert-butyl-4-hydroxybenzylidene)-amino]but- 2-enedinitrile, 2-(3,5-di-tert-butyl-4-hydroxybenzylidene)indan-1,3-dione, 2-malononitrile, 2-(4-chlorophenyl)indole, N-(2,4,5-trichlorophenyl)salicylanilide, 2,3-dimethyl-5-cyano-7-ethylindole, 4-bromo-2-(4-chlorophenyl)-5-trifluoromethyl-1H-pyrrole-3-carbonitrile, N-(5,7-dimethyl-1H-indol-3-ylmethylene)-3-trifluoromethyl-benzamide, 2,4-Dinitrophenol, carbonyl cyanide-p-trifluoromethoxy-phenylhydrazone, 2-(5-bromo-1H-indol-3-ylmethylene)malononitrile, 2-((5-chloro-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-(2-phenyl-3-indolylmethylene)malononitrile Malononitrile, 2-(2-chloro-1H-indol-3-ylmethylene)malononitrile, 2-(5-nitro-1H-indol-3-ylmethylene)malononitrile, 2-(2-methyl-5-nitro-1H-indol-3-ylmethylene)malononitrile, 3-bromo-5-tert-butyl-N-(2-chloro-4-nitrophenyl)-6-hydroxy-2-methylbenzamide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-3-isopropylbenzamide N-(2-chloro-4-nitrophenyl)-2-hydroxy-3-isopropyl-6-methylbenzamide, 3,5-di-tert-butyl-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide, 3-bromo-N-(2-chloro-4-nitrophenyl)-6-hydroxy-5-isopropyl-2-methylbenzamide, 3-tert-butyl-5-chloro-N-(4-chloro-3-trifluoromethylphenyl)-2-hydroxy-6-methyl-benzamide benzamide, 3-tert-butyl-5-chloro-N-(4-cyano-3-trifluoromethylphenyl)-2-hydroxy-6-methylbenzamide, 2-hydroxybiphenyl-3-carboxylic acid (2-chloro-4-nitrophenyl)-amide, 3-tert-butyl-N-(2-chloro-4-nitrophenyl)-2-hydroxy-5-methylbenzamide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-6-isopropyl-3-methylbenzamide, N-(3,5-bistrifluoromethylphenyl)-3-tert-butyl-5-chloro-2-hydroxy-6-methylbenzamide, 3-tert-butyl-5-chloro-N-(2-fluoro-5-trifluoromethylphenyl)-2-hydroxy-6-methylbenzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-3-trifluoromethylphenyl)benzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3- Bromo-5-tert-butyl-N-(2-chloro-4-cyanophenyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(2-chloro-5-trifluoromethylphenyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methylbenzamide amide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-{5-chloro-4-[(4-chlorophenyl)cyanomethyl]-2-methylphenyl}-6-hydroxy-2-methylbenzamide, 3-bromo-6-hydroxy-5-isopropyl-2-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-N-( 4-nitro-2-trifluoromethyl-phenyl)benzamide, 3-tert-butyl-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3-bromo-N-(3,5-di-tert-butyl-4-hydroxyphenyl)-5-tert-butyl-6-hydroxy-2-methylbenzamide, N-(3,5-di-tert-butyl-4-hydroxybenzylidene)-3-bromo-5-tert-butyl-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-[(3,5-di-tert-butyl-4-hydroxybenzylidene)amino]-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-6-hydroxy-N-(4-isopropyl-2-trifluoromethylphenyl)-2-methylbenzamide, N-(3,5-di-tert-butyl-4-hydroxybenzylidene)-3-fluoro-5-trifluoromethylbenzamide, 3-fluoro-N-(4-nitro-3-trifluoromethylphenyl)-5-trifluoromethylbenzamide, N-(2,4,5 -trichlorophenyl)-3-fluoro-4-trifluoromethylbenzamide, 4-fluoro-N-(4-nitro-3-trifluoromethylphenyl)-3-trifluoromethylbenzamide, 3-(3,5-di-tert-butyl-4-hydroxyphenyl-2-(5,7-dimethyl-1H-indol-3-ylmethylene)acrylonitrile, 2-acetyl-3-(3,5-bis-trifluoromethylphenyl)acrylic acid ethyl ester, 2-(3,5-di-tert-butyl-4-hydroxybenzyl)malononyl tolyl, 2-(3,5-di-tert-butyl-4-hydroxybenzyl)malononitrile, 2,6-di-tert-butyl-4-nitrophenol, 2-tert-butyl-4,6-dinitrophenol, 3-(3,5-di-tert-butyl-4-hydroxybenzyl)-2-pyridin-2-yl-acrylonitrile, 2-(3,5-di-tert-butyl-4-hydroxyphenyl)malononitrile, 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-(diethylphosphonate)propenenitrile , 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-nitrophenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-pyridin-4-yl-acrylonitrile, 2-(3,5-bis-trifluoromethylphenyl)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-trifluoromethoxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-trifluoromethyl-phenyl)acrylonitrile, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)but-2-enoic acid ethyl ester, N-(4-chlorophenyl)-2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylamide, (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-methanesulfonylacrylonitrile, (E)-2-(4-chlorobenzenesulfonyl)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-fluorobenzenesulfonyl)acrylonitrile, (E)-2-benzenesulfonyl-3- (3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, (E)-3-(3,5-bis-trifluoromethylphenyl)-2-(propane-2-sulfonyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(hexane-1-sulfonyl)acrylonitrile, 2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 2-(4-bromo-benzenesulfonyl)-3-acrylonitrile, 2-(3,10. The method of claim 9, wherein the compound is selected from the group consisting of 5-di-tert-butyl-4-hydroxybenzylidene)acrylonitrile, 5-bromo-3-tert-butyl-N-(2-chloro-4-cyanophenyl)-2-hydroxybenzamide, 5-bromo-3-tert-butyl-N-(4-cyanophenyl)-2-hydroxybenzamide, 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-N-(2-trifluoromethylphenyl)benzamide, 2-(2-bromo-1H-indol-3-ylmethylene)malononitrile, 2-(7-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, 2-(5-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, pharmaceutically acceptable salts thereof, derivatives thereof, and combinations thereof.

11. 1. A system for monitoring at least one body metric information for a patient (100) having metabolic syndrome and / or related disorders, using an electronic device associated with a measuring device for measuring said body metric information, said system comprising: (a) a patient monitoring module installed in said patient electronic device and interface (160a); (b) at least one measuring device (140) for measuring the body metric information connectable to the patient's electronic device and interface (160a); (c) linking means (180) between the electronic device and interface (160a) of the patient and the measuring device (140) for measuring the body metric information; (d) the patient monitoring module is configured to (i) collect (101) patient identification information (102a) and / or the body metrics information (102c); (ii) register (142) and store (143) the measured (141) body metrics information (102c) of the patient in a database (103); (iii) store the information in the database (103) for incorporation into a medical record (102b); and (iv) identify the patient (100) as having metabolic syndrome and / or (v) providing the patient (100) with a medical professional (110) specializing in the metabolic syndrome and / or related disorders, who will assess the patient's health status, provide the patient with the medical status (111b), record the status in the patient's medical record (102b), and provide the patient with a course of treatment (111c) for the treatment of metabolic syndrome and / or related disorders or for the prevention of metabolic syndrome and / or related disorders; and (v) providing the patient (100) through a pharmacy (120) with a useful drug for the prevention, mitigation, or management of metabolic syndrome and / or related disorders. (vi) establishing a connection (151) with at least one measuring device (140) for measuring said body metric information; and (vii) measuring (141), recording (142) and storing (143) said body metric information (102c) obtained from said at least one measuring device (140) for measuring said body metric information in said database (103). 43), (viii) allowing the medical professional (110) specializing in metabolic syndrome and / or related disorders to access (170) the patient's medical records for the purpose of assessing the patient's health status and adjusting or maintaining a course of treatment (113), and optionally (ix) establishing (114) communication between the patient (100) and the medical professional (110) at set intervals or upon request of the patient or the medical professional.

12. 12. The system of claim 11, for monitoring at least one of the body metric information of the patient (100), wherein the body metric information is selected from weight, body mass index, body fat percentage, height, muscle, water, visceral fat, bone, metabolism, protein, obesity index, body age, lean body mass, oxygenation, body oxygenation quantified in urine, vitamins and minerals, blood glucose, blood pressure, LDL cholesterol, HDL cholesterol, triglycerides, urine glucose, pedometer, heart rate, fasting blood glucose, post-load blood glucose, total cholesterol, total bilirubin, alanine transaminase, aspartate aminotransferase, and / or body temperature.

13. 13. The system for monitoring at least one body metric information of the patient (100) according to claim 11 or 12, wherein the measuring device (140) is selected from a weight scale, ORP, vitamin stick, blood glucose meter, oximeter, smart watch, smart bracelet, smart clothing, patch, tattoo, implant, hearing aid, helmet, electrode, chest strap, pedometer, medical equipment for quantification of biochemical parameters.

14. A system for monitoring at least one body metric information of the patient (100) according to any one of claims 11 to 13, comprising: The pharmaceutical composition comprising the medicament (130) useful for the prevention, alleviation or management of metabolic syndrome and / or related diseases may comprise a chemical uncoupler of oxidative phosphorylation, tyrphostin AG17, orlistat, L-carnitine, benzphetamine, phendimetrazine, diethylpropion, liraglutide, naltrexone, phentermine, topiramate, glibenclamide, metformin, acarbose, canagliflozin, dapagliflozin, saxagliptin, dulaglutide, empagliflozin, exenatide, lixisenatide, semaglutide, CBD, sibutramine, hydroxycitric acid, coenzyme q10, chromium picolinate, gamma-linolenic acid, resveratrol, omega-3 fatty acids, antioxidants, vitamins, vitamin B, vitamin C, adrenal extract, pantothenic acid, turmeric, longa), white bayberry bark, white bayberry (Myrica cerifera), indica rice (Oryza sativa L. indica), tea plant (Camellia sinensis), cacao (Theobroma cacao), amla (Emblica officinalis), yerba mate (Ilex paraguariensis), Cascara sagrada bark, Cascara sagrada (Rhamnus purshiana), Acacia nilotica, persimmon, blueberry leaf leaf), grape seed, Cha de bougre (Cordia salicifolia), St. John's wort (Hypericum perforatum), Pururia thomsonn, capers (Capparis spinosa), garden vine (Gymnema sylvestre), elderberry, Sambicus, bitter orange (Citrus aurantium), robusta coffee tree (Coffea canefora), purple myrtle (Sygium cumini), rosemary (Rosmarinus officinalis), ginger (Zingiberofficinalis), Cassia nomadicum, Cissus quadrangularis, Phaseolus vulgaris, Licorice root, Fenugreek, Yohimbine, White willow, Cordyceps sinensis, Ashwagandha, Astragalus, Gingseng, Schisandra, Siberian ginseng, Asian ginseng Gingseng, Guggul Gagal Mukul, Indian Makal (Commiphora mukul), Momordica charantia, Garcinia cambogia, Marshmallow (Althaea officinalis), Bougainvillea spectabilis, Medicago sativa, Valeriana officinalis, Damiana, Elderberry (Sambucusnigra), Capsicum, Allium, calcium myristate, magnesium myristate, tetradecylthioacetic acid (TTA), thyroid hormones or precursors thereof, thyroid enhancers, Kreb cycle metabolites, UCP-1, UCP-2, UCP-3, endogenous uncoupling proteins of PUMP (plant uncoupling mitochondrial protein) or precursors thereof, agonists or enhancers, leucine, valine, isoleucine, glutamine, proline, tyrosine, conjugated linoleic acid, adrenergic agents, fatty acids or esters, beta agonists, glucagon, albumin, vasopressin, ubiquinone, coenzyme Q1, coenzyme Q2, melatonin, fatty acid esters of estrogen, glutamine, valine, isoleucine, glutamine, proline, tyrosine, conjugated linoleic acid, thiamin monophosphate (THP), ... Co-mannan, menthol, peppermint oil, thyme oil, elemental sulfur and policosanol, insulin or insulin analogues, acetohexamide, carbutamide, chlorpropamide, glibenclamide, glibornuride, gliclazide, glimepiride, glipizide, tolazamide, tolbutamide, (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol or Glyset)(1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)-cyclohexane-1,2,3,4-tetraol), (RS)-5-[4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione, (RS)-5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)thiazolidine-2,4-dione, 5-[(4-[2-([6-(4-methoxyphenoxyl)pyrimidin-4-yl]-methylamino)ethoxy]phenylmethyl]-1,3-thiazolidine-2,4-dione, (RS)-5-(4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2 -yl)methoxy)benzyl)thiazolidine-2,4-dione, (S)-(+)-2-ethoxy-4-[2-(3-methyl-1-[2-(piperidin-1-yl)phenyl]butylamino)-2-oxoethyl]benzoic acid, 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid, (2S)-2-benzyl-4-[(3aR,7aS)-octahydro-2H-isoindol-2-yl]-4-oxobutanoic acid, L-ornithine, L- Tyrosine, L-tryptophan, L-phenylalanine, conjugated linoleic acid, gamma-linolenic acid, chromium picolinate, glucose tolerance factor, vanadyl sulfate, gymnema sylvestre, bromelain, pancreatin, gymnema sylvestre 10, curcumin, barberry, bearberry, silymarin, fruit fly, choline, inositol, human growth hormone, DHEA, fucoxanthin, caffeine, xanthenes, cola nut, psyllium syrup, yerba mate, guarana, ginseng, medium-chain triglycerides The system is selected from the group consisting of lido, hydroxycitric acid (HCA), kelp, lecithin, dihydroxyacetone, pyruvic acid, creatine, iodine, niacin, bladderwrack, white kidney bean extract, glucomannan, chitosan, resveratrol, resveratrol derivatives, vitamin D, hCG, capsaicin, chia, hoodia, apple cider vinegar, coconut oil, bitter orange, B vitamins and pharmaceutically acceptable salts and derivatives thereof, and combinations thereof.

15. 15. The system for monitoring at least one body metric information of the patient (100) according to claim 14, wherein the chemical uncoupler of oxidative phosphorylation is selected from the group consisting of 4,4-bis-(4-hydroxy-3-nitrophenyl)valeric acid, 4-methoxy-2-nitrophenol, 4-hydroxy-3-nitroacetophenone, 7-hydroxy-4-methyl-8-nitrochromen-2-one, 3-tert-butyl-5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-6-methylbenzamide, N-1-[4-cyano-3-(trifluoromethyl)phenyl]-3,5-di-(trifluoromethyl)benzamide, N-(4-cyanophenyl)benzamide, 2'-chloro-1-hydroxy-4'-nitro-2-naphthanilide, N-(2-chloro-4-bromophenyl)-5- Bromosalicylanilide, N-(2-chloro-4-nitrophenyl)-3-tert-butyl-6-methylsalicylanilide, (3,5-di-tert-butyl-4-hydroxybenzyl)triphenylphosphonium bromide, 3,5-di-tert-butyl-4-hydroxybenzyl)tricyclohexylphosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)tributylphosphonium bromide, (3,5-di-tert-butyl-4-hydroxybenzyl)trioctylphosphonium bromide, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylic acid ethyl ester, 2-(3,5-di-tert-butyl-4-hydroxybenzylidene)malonic acid diethyl ester, 2-amino-S-[(3,5-di-tert-butyl-1 -4-hydroxybenzylidene)-amino]but-2-enedinitrile, 2-(3,5-di-tert-butyl-4-hydroxybenzylidene)-indan-1,3-dione, 2-malononitrile, 2-(4-chlorophenyl)-indole, N-(2,4,5-trichlorophenyl)salicylanilide, 2,3-dimethyl-5-cyano-7-ethylindole, 4-bromo-2-(4-chlorophenyl)-5-trifluoromethyl-1H-pyrrole-3-carbonitrile, N-(5,7-dimethyl-1H-indol-3-ylmethylene)-3-trifluoromethyl-benzamide, 2,4-Dinitrophenol, carbonyl cyanide-p-trifluoromethoxy-phenylhydrazone, 2-(5-bromo-1H-indol-3-ylmethylene)-malononitrile, 2-((5-chloro-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-((5-methyl-1H-indol-3-yl)methylene)malononitrile, 2-(2-phenyl-3-indolylmethylene) Malononitrile, 2-(2-chloro-1H-indol-3-ylmethylene)malononitrile, 2-(5-nitro-1H-indol-3-ylmethylene)malononitrile, 2-(2-methyl-5-nitro-1H-indol-3-ylmethylene)malononitrile, 3-bromo-5-tert-butyl-N-(2-chloro-4-nitrophenyl)-6-hydroxy-2-methylbenzamide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-3-isopropylbenzamide Amide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-3-isopropyl-6-methylbenzamide, 3,5-di-tert-butyl-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide, 3-bromo-N-(2-chloro-4-nitrophenyl)-6-hydroxy-5-isopropyl-2-methylbenzamide, 3-tert-butyl-5-chloro-N-(4-chloro-3-trifluoromethylphenyl)-2-hydroxy-6-methylbenzamide benzamide, 3-tert-butyl-5-chloro-N-(4-cyano-3-trifluoromethylphenyl)-2-hydroxy-6-methylbenzamide, 2-hydroxybiphenyl-3-carboxylic acid (2-chloro-4-nitrophenyl)-amide, 3-tert-butyl-N-(2-chloro-4-nitrophenyl)-2-hydroxy-5-methylbenzamide, N-(2-chloro-4-nitrophenyl)-2-hydroxy-6-isopropyl-3-methylbenzamide, N-(3,5-bistrifluoromethylphenyl)-3-tert-butyl-5-chloro-2-hydroxy-6-methylbenzamide, 3-tert-butyl-5-chloro-N-(2-fluoro-5-trifluoromethylphenyl)-2-hydroxy-6-methylbenzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-3-trifluoromethylphenyl)benzamide, 3-tert-butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3 -bromo-5-tert-butyl-N-(2-chloro-4-cyanophenyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(2-chloro-5-trifluoromethylphenyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methyl benzamide, 3-bromo-5-tert-butyl-N-(3,5-di-tert-butyl-4-hydroxybenzyl)-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-{5-chloro-4-[(4-chlorophenyl)cyanomethyl]-2-methylphenyl}-6-hydroxy-2-methylbenzamide, 3-bromo-6-hydroxy-5-isopropyl-2-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-N- (4-nitro-2-trifluoromethylphenyl)benzamide, 3-tert-butyl-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethylphenyl)benzamide, 3-bromo-N-(3,5-di-tert-butyl-4-hydroxyphenyl)-5-tert-butyl-6-hydroxy-2-methylbenzamide, N-(3,5-di-tert-butyl-4-hydroxybenzylidene)-3-bromo-5-tert-butyl-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-N-[(3,5-di-tert-butyl-4-hydroxybenzylidene)amino]-6-hydroxy-2-methylbenzamide, 3-bromo-5-tert-butyl-6-hydroxy-N-(4-isopropyl-2-trifluoromethylphenyl)-2-methylbenzamide, N-(3,5-di-tert-butyl-4-hydroxybenzylidene)-3-fluoro-5-trifluoromethylbenzamide, 3-fluoro-N-(4-nitro-3-trifluoromethylphenyl)-5-trifluoromethylbenzamide, N-(2,4,5 -trichlorophenyl)-3-fluoro-4-trifluoromethylbenzamide, 4-fluoro-N-(4-nitro-3-trifluoromethylphenyl)-3-trifluoromethylbenzamide, 3-(3,5-di-tert-butyl-4-hydroxyphenyl-2-(5,7-dimethyl-1H-indol-3-ylmethylene)acrylonitrile, 2-acetyl-3-(3,5-bis-trifluoromethylphenyl)acrylic acid ethyl ester, 2-(3,5-di-tert-butyl-4-hydroxybenzyl)malononyl tolyl, 2-(3,5-di-tert-butyl-4-hydroxybenzyl)malononitrile, 2,6-di-tert-butyl-4-nitrophenol, 2-tert-butyl-4,6-dinitrophenol, 3-(3,5-di-tert-butyl-4-hydroxybenzyl)-2-pyridin-2-yl-acrylonitrile, 2-(3,5-di-tert-butyl-4-hydroxyphenyl)malononitrile, 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-(diethylphosphonate)propenenitrile , 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-nitrophenyl)-acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-pyridin-4-yl-acrylonitrile, 2-(3,5-bis-trifluoromethylphenyl)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-trifluoromethoxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-trifluoromethylphenyl)acrylonitrile, 2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)but-2-enoic acid ethyl ester, N-(4-chlorophenyl)-2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylamide, (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-methanesulfonylacrylonitrile, (E)-2-(4-chlorobenzenesulfonyl)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(4-fluorobenzenesulfonyl)acrylonitrile, (E)-2-benzenesulfonyl-3- (3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, (E)-3-(3,5-bis-trifluoromethylphenyl)-2-(propane-2-sulfonyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(hexane-1-sulfonyl)acrylonitrile, 2-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile, 2-(4-bromo-benzenesulfonyl)-3-acrylonitrile, 2-(3,The system is selected from the group consisting of 5-di-tert-butyl-4-hydroxybenzylidene)acrylonitrile, 5-bromo-3-tert-butyl-N-(2-chloro-4-cyanophenyl)-2-hydroxybenzamide, 5-bromo-3-tert-butyl-N-(4-cyanophenyl)-2-hydroxybenzamide, 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-N-(2-trifluoromethylphenyl)benzamide, 2-(2-bromo-1H-indol-3-ylmethylene)malononitrile, 2-(7-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, 2-(5-bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile, pharmaceutically acceptable salts thereof, derivatives thereof, and combinations thereof.

Images